Estimation of Option for Biotech Companies
The evaluation of efficiency of drug development process is being investigated, taking into account the ability of further drug development in different phases and in companies with different specialization. Same estimations for biotech drugs Research and Production Chain (RPC) were carried out in government enterprise «Vector» in Russia [1]. This article is aimed at the investigation of possibility of application of options model to estimate the efficiency of further development process in biotechnology RPC (USA biotech companies were used in estimation because they achieved high level of commercial applications giving a good empirical data for estimation of option).